Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease

Area of Science:

• Immunology
• Nephrology
• Pharmacology

Background:

• The complement system is a crucial component of the innate immune system.
• Its role in renal diseases, including pauci-immune and immune-complex types, is increasingly recognized.
• Despite eculizumab's approval in 2011, no new complement antagonists have reached clinical practice.

Purpose of the Study:

• To review the role of complement in various renal diseases.
• To summarize novel complement inhibitors currently in clinical development.
• To highlight potential therapeutic benefits of complement inhibition in nephrology.

Main Methods:

• Literature review of complement's role in renal pathology.
• Survey of complement inhibitors in preclinical and clinical trials.
• Analysis of therapeutic targets within the classical, lectin, and alternative complement pathways.

Main Results:

• Complement system activation is implicated in the pathogenesis of diverse kidney diseases.
• A range of novel therapeutic agents, including oral small molecules and RNA interference therapies, are under investigation.
• These agents target different components of the complement cascade.

Conclusions:

• Complement inhibitors hold significant therapeutic promise for managing a spectrum of renal diseases.
• Ongoing research and clinical trials are paving the way for new treatment options in nephrology.
• Targeting the complement system represents a promising strategy for kidney disease intervention.